AbCellera Awaits Phase 2 Data for ABCL635 Menopause Treatment
AbCellera awaits Phase 2 clinical data for ABCL635, its experimental non-hormonal menopause treatment, as the biotech company approaches a major clinical catalyst. The stock traded more than 11% higher in pre-market, extending a rally that saw gains in nine of the past 10 sessions and added
JAZZ2.31%
LucasBennett·08-10 12:14
